# Prescription Monitoring Program Advisory Council State of Louisiana

July 12, 2023

# **MINUTES**

A meeting of the Louisiana Prescription Monitoring Program (PMP) Advisory Council scheduled to meet on Wednesday, July 12, 2023 at the office of the Louisiana Board of Pharmacy, 3388 Brentwood Drive in Baton Rouge, Louisiana 70809, convened at 1:13 p.m. to consider the following:

#### AGENDA

- 1. Call to Order
- 2. Amendments to Council Roster
- 3. Quorum Call
- 4. Call for Additional Agenda Items & Adoption of Agenda
- 5. Consideration of Draft Minutes from Previous Meeting: January 11, 2023, and notes from April 12, 2023
- 6. Opportunity for Public Comment
- 7. Election of Council Officers: Chair and Vice Chair
- 8. Review of Program Operations
- 9. Review of Legislative and Regulatory Activity
- 10. New Agenda Items Added During Meeting
- 11. Calendar Notes
- 12. Adjourn

## **Advisory Council Representatives/Designees present:**

- Mr. Marty McKay, Council Chairman, President of the Louisiana Board of Pharmacy;
- > Ms. Lauren Bailey, Council Vice-Chair, Designee for the President of the Louisiana State Medical Society;
- Ms. Patricia Wilton, Designee for the President of the Louisiana State Board of Medical Examiners;
- Ms. Monique Calmes, Designee for the President of the Louisiana State Board of Nursing;
- Mr. Randal Johnson, President of the Louisiana Independent Pharmacies Association;
- Ms. Jacqueline Sanchez, Designee for the President of the Louisiana District Attorneys Association;
- > Ms. Shelly Dupre, Designee for the President of the National Association of Chain Drug Stores;
- > Dr. Jonathan Bowman, Designee for the President of the Optometry Association of Louisiana;
- Ms. Crystal Carter, Designee for the President of the Louisiana Pharmacists Association; and
- Ms. Annette Droddy, Designee for the President of the Louisiana Dental Association.

#### Others present:

- Mr. M. Joseph Fontenot, Jr., Executive Director, Louisiana Board of Pharmacy;
- Mr. Carlos M. Finalet, III, General Counsel, Louisiana Board of Pharmacy;
- Ms. Nerissa I. Montgomery, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy;
- Ms. Reshmi Ravindranath, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy;
- Ms. Christina A. Howland, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy;
- Ms. Carley P. Leach, Administrative Coordinator 3, PMP-Staff, Louisiana Board of Pharmacy;
- Ms. Kelly Calmes, Breazeale Sachse & Wilson, LLP; and
- Ms. Sarah Perkins, Breazeale Sachse & Wilson, LLP.

# Advisory Council Members Absent:

- The President of the Louisiana State Board of Dentistry;
- The President of the Louisiana State Board of Optometry Examiners;
- ➤ The President of the Louisiana Academy of Physicians Assistants;
- The Superintendent of the Louisiana State Police;
- The Administrator of the United States Drug Enforcement Administration;
- > The Speaker of the Louisiana House of Representatives;
- The President of the Louisiana Senate;
- The Chairman of the House Committee on Health and Welfare:
- > The Chairman of the Senate Committee on Health and Welfare;

## **PMP Advisory Council Meeting Minutes**

July 12, 2023 Page 2

## **Advisory Council Members Absent (continued):**

- > The Secretary of the Department of Health;
- > The President of the Louisiana Association of Nurse Practitioners;
- > The President of the Louisiana Sheriffs' Association:
- > The President of the Pharmaceutical Research and Manufacturers of America; and
- > The President of the Louisiana Academy of Medical Psychologists.

#### Amendments to Council Roster

Mr. McKay reported the amendments to the Council Roster due to the change in leadership since the last Council meeting.

# **Quorum Call**

Mr. McKay was unable to establish a quorum as only ten members were present. Eleven members are required by R.S. 40:1055(B) to constitute a quorum. Informational meeting continued but no business could be conducted without the required quorum.

# Call for Additional Agenda Items & Adoption of Agenda

No additional agenda items introduced; adoption of agenda postponed to the next meeting.

Consideration of Draft Minutes from Previous Meeting: January 11, 2023, and notes from April 12, 2023

Approval of minutes and notes was delayed until the next meeting.

# **Opportunity for Public Comment**

No public comments.

#### **Election of Council Officers: Chair and Vice Chair**

Election of Council Officers was delayed until the next meeting.

#### **Review of Program Operation**

Joe Fontenot, Executive Director, presented statistical information regarding the program to the council. (Attachment 1).

Mr. Fontenot explained there continues to be a consistent, downward trend in the number of controlled dangerous substance prescriptions and opioid prescriptions dispensed to Louisiana patients over time. The number of therapeutic marijuana recommendations dispensed has significantly increased since the availability of the raw form of therapeutic marijuana. Mr. Fontenot reported that both the AWARxE© and Gateway© searches continue to increase with more searches being done via the PMP integration component, Gateway©. He reminded the Council that the LDH - Office of Public Health - Bureau of Community Preparedness grant which currently pays for the Gateway© integration license fees will expire in September of 2023. Additional funding for the upcoming year is being sought. Mr. Fontenot explained we have started sharing data with Ohio. The contract with Appriss, currently known as Bamboo Health, will end as of December 31, 2023. The Invitation to Bid has been completed and will be posted for public bids.

Mr. Fontenot mentioned receiving inquiries regarding the collection of all prescription data by the PMP. Council discussed the potential pros and cons.

Mr. Fontenot discussed potential regulatory proposals to remove naloxone from the drugs of concern and remove the explicit language for butalbital. (Attachment 2).

Mr. Fontenot also discussed the current record retention regulation which is inconsistent with the intent of the PMP program.

## **Review of Legislative and Regulatory Activity**

Mr. Fontenot discussed House Bill #133 by Representative Chris Turner passed in this legislative session. The legislation changed the PMP Advisory Council meeting frequency from quarterly to at least once annually and added the exception for electronic meetings. (Attachment 3).

# **PMP Advisory Council Meeting Minutes**

July 12, 2023 Page 3

# New Agenda Items Added During Meeting

No new agenda items added.

# **Calendar Notes**

The Council discussed future meeting dates which remain to be decided.


# <u>Adjournment</u>


With no business conducted, the meeting was adjourned at 2:02 p.m.


I certify that the foregoing are true and accurate minutes.


Joe Fontenot Executive Director Louisiana Board of Pharmacy

















	Number of Providers	Number of	Number of PMP	Number of PMP
	Eligible	Providers with	Requests by	Requests by
	for PMP Access	Active PMP Access	Providers through	Providers through
	(as of 06/30/2023)	Privileges (as of	AWARxE®	Gateway <sup>®</sup>
PMP Healthcare Provider Role		06/30/2023)	During 2023Q2	During 2023Q2
Physician (MD, DO)	13,799	9,508	552,927	6,624,033
Nurse Practitioner (APRN)	5,089	4,019	239,659	620,287
Dentist (DDS)	2,216	1,497	5,808	4,743
Physician Assistant (PA)	1,304	1,030	44,850	74,145
Optometrist (OD)	364	150	4	0
Podiatrist (DPM)	169	123	2,287	0
Medical Psychologist (MP)	96	94	8,850	11,204
Medical Intern/Resident	1,891	1,251	10,246	194,665
Prescriber's Delegate	N/A	3,817	187,619	N/A
Pharmacist (PST)	9,621	5,228	1,315,687	2,119,440
Pharmacist's Delegate	N/A	1,690	149,043	N/A
Totals	34,549	28,407	2,516,980	9,648,517

7









HB NO. 133	ENROLLED

1	Section 2. R.S. 42:17.4 is hereby enacted to read as follows:
2	§17.4. Exception for meetings of the Prescription Monitoring Program Advisory
3	Council
4	A. Notwithstanding any other provision of law to the contrary, the
5	Prescription Monitoring Program Advisory Council, as provided in R.S. 40:1005,
6	may conduct and its members may attend and participate in a meeting via electronic
7	means if the Louisiana Board of Pharmacy, the advisory council, and its presiding
8	officer comply with all of the requirements of this Section.
9	B. No later than twenty-four hours prior to a meeting conducted pursuant to
10	the provisions of this Section, the advisory council shall provide for all of the
11	following:
12	(1) The notice and agenda for the meeting, which shall be posted on the
13	website of the Louisiana Board of Pharmacy, emailed to any member of the public
14	or the news media who requests notice of meetings of the public body, and widely
15	distributed to every known news media outlet that broadcasts or publishes news
16	within the geographic area within the jurisdiction of the Louisiana Board of
17	Pharmacy.
18	(2) Detailed information regarding how members of the public may
19	participate in the meeting and submit comments regarding matters on the agenda,
20	which information shall be posted on the website of the Louisiana Board of
21	Pharmacy, emailed to any member of the public or the news media who requests
22	notice of meetings of the public body, and widely distributed to every known news
23	media outlet that broadcasts or publishes news within the geographic area within the
24	jurisdiction of the Louisiana Board of Pharmacy.
25	C. For each meeting conducted pursuant to this Section, all of the following
26	requirements shall apply:
27	(1) The advisory council shall provide a mechanism to receive public
28	comment electronically both prior to and during the meeting.

HB NO. 133 **ENROLLED** 1 (2) The advisory council shall properly identify and acknowledge all public 2 comments during the meeting and shall maintain those comments in its record of the 3 meeting. 4 (3) The presiding officer of the advisory council shall ensure that each 5 person participating in the meeting is properly identified. (4) The presiding officer shall ensure that all parts of the meeting, excluding 6 7 any matter discussed in executive session, are clear and audible to all participants in 8 the meeting including the public. 9 D. For the purposes of this Section, the following words and phrases have 10 the following meanings: (1) "Meeting via electronic means" means a meeting occurring via 11 12 teleconference or video conference. 13 (2) "Teleconference" means a method of communication which enables 14 persons in different locations to participate in a meeting and to hear and otherwise 15 communicate with each other. 16 (3) "Video conference" means a method of communication which enables 17 persons in different locations to participate in a meeting and to see, hear, and 18 otherwise communicate with each other. SPEAKER OF THE HOUSE OF REPRESENTATIVES PRESIDENT OF THE SENATE GOVERNOR OF THE STATE OF LOUISIANA

APPROVED: \_\_\_\_\_

#### Title 46

# PROFESSIONAL AND OCCUPATIONAL STANDARDS

#### Part LIII: Pharmacists

#### Chapter 29. Prescription Monitoring Program

#### §2901. Definitions

A. As used in this Chapter, the following terms shall have the meaning ascribed to them unless the context clearly indicates otherwise.

\* \* \*

Drugs of Concern—drugs other than controlled substances as defined by rule whose use requires tracking for public health purposes or which demonstrate a potential for abuse, including any material, compound, mixture, or preparation containing any quantity of the following substances, including its salts, esters, ethers, isomers, and salts of isomers [whenever the existence of such salts, esters, ethers, isomers, and salts of isomers is possible within the specific chemical designation]:

- a. butalbital when in combination with at least 325 milligrams of acetaminophen per dosage unit.
- b. naloxone.
- e. promethazine when present in oral liquid formulation.

d.c. gabapentin.

AUTHORITY NOTE: Promulgated in accordance with R.S. 40:1011.

HISTORICAL NOTE: Promulgated by the Department of Health and Hospitals, Board of Pharmacy, LR 33:1345 (July 2007), amended LR 36:755 (April 2010), effective September 1, 2010, LR 39:314 (February 2013), LR 40:1095, 1096 (June 2014), LR 41:684 (April 2015), amended by the Department of Health, Board of Pharmacy, LR 45:42 (January 2019), LR 47:84 (January 2021), repromulgated LR 47:248 (February 2021), amended LR